Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The treatment method of osteoporosis in patients undergoing hemodialysis (HD) has not been established, as there is insufficient evidence regarding the treatment of osteoporosis. The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 guidelines suggest that determining the bone marrow density (BMD) of HD patients is useful. In 2018, we began treating HD patients' osteoporosis with denosumab. Herein, we describe the effects of the treatment.
This was a single-center prospective observational study of 42 HD patients (age 71.2±9.7 yrs; 24 females, 18 males) treated for osteoporosis with denosumab in our hospital during 2018–2024. The average observational period was 3.8±2.2 years. We introduced osteoporosis treatment with alendronate in 2011, ibandronate in 2016, and denosumab in 2018. The patients' BMD values including the lumbar spine, femoral neck, and total hip were determined by dual-energy X-ray absorptiometry. We administered alendronate or ibandronate to patients whose first T-score was ≤-2.5. We checked the patients' BMD measured every year from 2011. Beginning in 2018, if a patient's T-score did not improve after the second year, we changed the medication to denosumab. We evaluated the patients' yearly BMD measurements and their yearly bone metabolism marker values, i.e., parathyroid hormone (PTH), bone alkaline phosphatase (BAP), and tartrate-resistant acid phosphatase 5b (TRACP-5b).
We investigated sex, age, existence of diabetes, hemodialysis period, and observational period. One year after the treatment, only the mean T-score of the lumbar spine significantly improved during the study period (p=0.01); those of the femoral neck and total hip did not. In a multiple regression analysis, low T-score before treatment and onset of diabetes were significantly associated with the improvement of T-scores.
The use of denosumab as a treatment of osteoporosis may be effective in hemodialysis patients, especially for the lumbar spine. Low T-score before treatment and onset of diabetes may affect the therapeutic effect.
